Abstract
Introduction: Short term studies of Elexacaftor/tezacaftor/ivacaftor (ETI) have shown increasing weight gain and modest improvements in GI symptoms. Since August 2020, all CF patients aged >12 years attending our Paediatric Service have been treated with ETI according to UK licencing. In this real-world study, we assessed changes in nutritional status after starting ETI, effects on the need for enteral feeding, use of pancreatic enzymes (PERT), endocrine function and medication.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
